Fate Therapeutics (FATE) Issued U.S. Patent No. 9,452,186 Covering Enhanced Hematopoietic Stem Cell Compositions

October 5, 2016 8:02 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Fate Therapeutics, Inc. (NASDAQ: FATE) announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,452,186 covering enhanced hematopoietic stem cell compositions. This newly-issued patent expands the Company’s significant intellectual property position covering ex vivo small molecule modulation of hematopoietic stem cells, which includes compositions and methods for enhanced lentiviral transduction and engraftment in the field of hematopoietic cell transplantation. The Company also has filed corresponding patent applications to seek similar patent protection for its hematopoietic stem cell compositions in key markets throughout the world, including Europe and Japan.

“Fate Therapeutics has pioneered the ex vivo use of small molecules, including prostaglandin pathway agonists, to modulate the safety and efficacy of hematopoietic cells prior to patient administration,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. “The issuance of this composition of matter patent, which covers the cellular composition of our lead product candidate ProTmune, validates that our ex vivo modulation approach can generate proprietary cellular immunotherapies. We believe this approach, which is backed by our extensive intellectual property, is broadly applicable to the development of hematopoietic cell therapies with novel biological properties and enhanced therapeutic functionality.”

This most recent patent, which expires in 2032, specifically covers compositions of hematopoietic stem and progenitor cells with increased CXCR4 gene expression and methods of increasing engraftment and reconstitution in patients by administering CXCR4-enhanced hematopoietic stem cells. CXCR4 signaling has been proven to play a pivotal role in the homing of hematopoietic stem and progenitor cells to the bone marrow in vivo and is critical to realizing the curative potential of hematopoietic cell transplantation. Importantly, these newly patented compositions and methods are independent of the specific modulators used to enhance the cells’ biological properties and therapeutic function.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Add Your Comment